Wang Hong Resigns as GSK China VP and Head of Respiratory Business

Recently, industry leaders have been frequently changing companies, and today there is another one!

On the afternoon of August 31, GlaxoSmithKline announced to its China-based employees that Wang Hong, Vice President and Head of the Respiratory Business Unit, had decided to resign for personal reasons, with August 31 being her last working day.

At this point, it had been less than eight months since Wang Hong assumed the position. GSK China also announced that, pending the appointment of a new head of the Respiratory Business Unit, Qi Xin, Vice President of GSK and General Manager of Prescription Drugs and Vaccines in China, would assume full interim management of the Respiratory Business Unit.

As previously introduced by Dami, Wang Hong graduated from Capital Medical University with a major in Pediatrics. She formerly served as National Sales Director at Lundbeck China. In 2008, she joined Merck Sharp & Dohme (MSD) as National Sales Director for antihypertensive products. In 2012, she moved to Pfizer, where she initially served as National Sales Director of the Vaccine Business Unit and was later promoted to Head of Pfizer China’s Vaccine Business Unit. In 2016, Wang Hong left Pfizer to join BD, serving as Head of the MPS Business Unit for Greater China.

In January 2018, Wang Hong returned to Lundbeck China, serving as Vice President of Sales, Marketing, and Commerce, as well as Chief Commercial Officer. On January 2 of this year, Lundbeck China announced Wang Hong’s departure, with her last working day being January 10. Subsequently, she joined GSK China on January 15 as Vice President and Head of the Respiratory Business Unit.